India’s tremendous economic growth since 2010 has propelled its life sciences sector to prominence, which is in a position to expand by another approximately 13 percent in the next five years, to an approximate value of $427 billion by 2030, according to a report by Ashish Singh, partner and head of India and Southeast Asia, real estate, with Actis, and Vishal Goel, managing director with Rx Propellant, which was published in the April issue of Institutional Real Estate Asia Pacific. Another telling statistic is that India also has more plants approved by the US Food and Drug Administration than any other country in the world, aside from the United States itself. “The world’s reliance on India to continue to produce vaccines and medicine is only likely to continue and grow in the long term, and those who are able to harness this opportunity will be strong winners,” note the report’s authors. “The current lack of specialised real estate infrastructure, howeve
